Patents by Inventor Michele Maio

Michele Maio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA HYPOMETHYLATING AGENTS FOR CANCER THERAPY
    Publication number: 20210338701
    Abstract: The present invention relates to a method of treating and/or preventing cancer comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 4, 2021
    Inventors: Michele MAIO, Sandra CORAL, Alessia COVRE
  • DNA hypomethylating agents for cancer therapy
    Patent number: 11083743
    Abstract: The present invention relates to a method of treating and/or preventing cancer comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: August 10, 2021
    Inventors: Michele Maio, Sandra Coral, Alessia Covre
  • DNA HYPOMETHYLATING AGENTS FOR CANCER THERAPY
    Publication number: 20150374731
    Abstract: The present invention relates to a method of treating and/or preventing cancer comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.
    Type: Application
    Filed: February 21, 2014
    Publication date: December 31, 2015
    Inventors: Sandra CORAL, Michele MAIO, Alessia COVRE
  • MARKERS OF MELANOMA AND USES THEREOF
    Publication number: 20130316931
    Abstract: The invention relates to a method for determining prognosis, predicting or monitoring response to therapy of patients affected by melanoma through the evaluation of the methylation of different genomic DNA sequences, including the Long Interspersed Nucleotide Element-1 (LINE-1) repetitive DNA sequences and/or the concomitant methylation profile of specific groups of genes defined as methylation signature.
    Type: Application
    Filed: February 1, 2012
    Publication date: November 28, 2013
    Applicants: CENTRO DI RIFERIMENTO ONCOLOGICO-INSTITUTO NAZIONALE TUMORI-AVIANO, AZIENDA OSPEDALIERA UNIVERSITARIA SENESE
    Inventors: Luca Sigalotti, Michele Maio